Their results are published in Chemical Science. Lead researcher Professor Andrew Wilson explained, "Aurora-A is an incomplete kinase, which means it relies on protein-protein interactions to ...

Takeda has decided that there is a future for its aurora kinase A inhibitor alisertib after it failed a phase 3 trial in lymphoma – but the company won't be taking the drug forward itself. Enter ...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on March 4, 2025, the Compensation ...

orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the ...

The Aurora family of cell cycle kinases regulates centrosome stability and thus influences cell cycle progression. Cytoskeletal remodelling proteins such as p21-activated kinase 1 (PAK1 ...

Inhibiting the AURKB enzyme significantly improves multiple measures of blood flow in rats with pulmonary arterial ...

Cell cycle events are controlled tightly by several kinase families including CDKs, Plks, and Aurora kinases. What is interesting about these kinases is that they don't always act alone.

orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024 ...

orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024 ...